314000-19-6

Basic information

• Product Name: 4-(3-Chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid
• Synonyms: 4-(3-Chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid;4-(3-Chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid
• CAS NO: 314000-19-6
• Molecular Formula: C₁₂H₁₁ClN₂O₃
• Molecular Weight: 266.68
• Mol File: 314000-19-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3-Chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid(314000-19-6)
• EPA Substance Registry System: 4-(3-Chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid(314000-19-6)

Safety Data

• Hazardous Substances Data: 314000-19-6(Hazardous Substances Data)

Usage

General Description

4-(3-Chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid, also known as Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that was used for the treatment of osteoarthritis, rheumatoid arthritis, and acute pain conditions. It belongs to the class of COX-2 inhibitors, which work by blocking the production of prostaglandins, compounds that cause inflammation, pain, and fever. Rofecoxib was withdrawn from the market in 2004 due to concerns about its cardiovascular safety, including an increased risk of heart attacks and strokes. Despite its withdrawal, research on Rofecoxib continues as scientists explore its potential use in other medical applications.

Upstream product

• 541-50-4 2-acetoacetic acid 
• 587-04-2 m-Chlorobenzaldehyde 
• 57-13-6 urea 

Relevant articles and documents

Targeting dormant tuberculosis bacilli: Results for molecules with a novel pyrimidone scaffold

Our inability to completely control TB has been due in part to the presence of dormant mycobacteria. This also renders drug regimens ineffective and is the prime cause of the appearance of drug-resistant strains. In continuation of our efforts to develop novel antitubercular agents that especially target dormant mycobacteria, a set of 55 new compounds belonging to the pyrimidone class were designed on the basis of CoMFA and CoMSIA studies, and these were synthesized and subsequently tested against both the dormant and virulent BCG strain of M. tuberculosis. Some novel compounds have been identified which selectively inhibit the dormant tuberculosis bacilli with significantly low IC50 values. This study reports the second molecule after TMC-207, having the ability to inhibit tuberculosis bacilli exclusively in its dormant phase. The synthesis was accomplished by a modified multicomponent Biginelli reaction. A classification model was generated using the binary QSAR approach - recursive partitioning (RP) to identify structural characteristics related to the activity. Physicochemical, structural, topological, connectivity indices, and E-state key descriptors were used for generation of the decision tree. The decision tree could provide insights into structure-activity relationships that will guide the design of more potent inhibitors. This paper reports the second molecule after TMC-207, with the ability to inhibit tuberculosis bacilli in its dormant phase. The paper reports molecules with a novel Pyrimidone Scaffold, the synthesis of which was accomplished with a modified multi-component Biginelli reaction. A classification model was generated using recursive partitioning (RP) technique to identify structural characteristics of the molecules with their varying activities.